All In Biotech

Drug Trial Radar · NCT03219008

Multi-Dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics

Multi-dimensional Diagnosis,Individualized Therapy,and Management Technique for Major Depressive Disorder:Based on Clinical and Pathological Characteristics

Last checked: Nov 19, 2026Latest source record: Oct 10, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingRandomized with 800 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

800

Planned (sponsor's estimate)

Start

Aug 1, 2017

Primary completion

Dec 2019

Study completion Dec 2020

Sponsor

Lead sponsor
Shanghai Mental Health CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Shanghai Jiao Tong University School of Medicine; Chinese Academy of Sciences; Shanxi Medical University; Central South University; Second Military Medical University; Peking University Sixth Hospital; First Affiliated Hospital Xi'an Jiaotong University; First Affiliated Hospital of Kunming Medical University; Air Force Military Medical University, China; Zhejiang University; Wuhan Mental Health Centre; Corning Hospital, Shenzhen City; the First Specialized Subject Hospital of Harbin; Renmin Hospital of Wuhan University; Seventh People's Hospital of Hangzhou; Shandong Mental Health Center
First posted
Jul 17, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Double (participant, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Major Depressive Disorder is one of the most common mental diseases,which increases health-care costs and the financial burden to families and societies. Considering its complex clinical symptoms and diversity of comorbidity, depressive disorder's recognition,diagnosis,and antihistone are based on symptomatology,which is lack of multidimensional diagnosis technique based on clinical pathological characteristics,as well as lack of individualized therapy strategy based on quantified evaluation. Besides, other physical diseases,such as nervous system diseases, cardiovascular diseases,endocrine diseases, have the high comorbidity of depressive disorder. However,there is no precise diagnosis technique or standardized therapy strategy. With all those taken into consideration,our study is aimed to adopt E-mental health and m-Health to explore multi-dimensional diagnosis, individualized therapy and management technique based on molecular biology,nerve electrophysiology,and neuroimaging technology etc.

Conditions

  • Depressive Disorder

Interventions

  • FluoxetineDrug

    Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.

  • fluoxetine + cognitive-behavioral treatment(CBT)Combination product

    the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.

  • fluoxetine + AmfebutamoneDrug

    Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.

  • physical treatment+fluoxetine+amfebutamoneCombination product

    the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.

  • FluvoxamineDrug

    Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.

  • Lithium+fluvoxamineDrug

    the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.

  • fluvoxamine + lithium + physical therapyCombination product

    the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.

  • Cognitive behavior treatment +fluvoxamineCombination product

    the investigators recommend behavioral therapy as well as drugs.

  • Mirtazapine/SNRIsDrug

    Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.

  • mirtazapine+ Cognitive behavior treatmentCombination product

    the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .

  • mirtazapine + SNRIsDrug

    the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.

  • mirtazapine + SNRIs + physical therapyCombination product

    the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.

  • TAU(treat as usual)Other

    patients in this group would receive therapy strategies according to their symptoms and preference.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in levels of microRNA,apolipoproteins, meta ion (Composite measure)Time frame: at 2,4,6,8,12 week.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ShanghaiMHC

    Shanghai, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.